BioLineRx (NASDAQ: BLRX) reported Q3 EPS of $0.00, $0.08 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $430 thousand versus the consensus estimate of $4.62 million.

For earnings history and earnings-related data on BioLineRx (BLRX) click here.